Specialty

Haematology: The treatment landscape in multiple myeloma has changed considerably over the past few years, resulting in a significant shift in the treatment paradigm in the relapsed/refractory multiple myeloma space. Join myeloma expert Prof. Hang Quach as she discusses the implications of these changes to current guidelines and treatment practices, and shares her thoughts on the optimal use of new therapies moving forward. 26-minute listen

Haematology: Earlier this year, the PBAC expanded the listing for carfilzomib to include once-weekly dosing in addition to twice-weekly dosing, in patients with relapsed/refractory multiple myeloma. In addition, daratumumab achieved its first listing, in combination with bortezomib and dexamethasone. Join haematologist Dr Wojt Janowski as he discusses these recent changes to the PBS, and learn how he manages relapsed/refractory myeloma patients in his clinic.  30-minute listen

General Specialty: Undergoing surgery increases the risk of VTE and many patients spend a lot of time in bed after surgery, leading to poor blood flow and the risk of developing a VTE: Join us in this interview where we discuss how surgeons can reduce the risks of developing blood clots in their patients.  23-minute listen

General Specialty: There are many patients across Australia and New Zealand that rely on dialysis each year. Management of anti-coagulation for these patients can be challenging and a number of approaches are available. In this interview we explore some of the different options available for prescribers and their patients.  20-minute listen

General Specialty: Osteoporosis and sarcopenia are two of the most prevalent chronic conditions in older persons and they share overlapping risk factors and also pathogenesis. When they occur together, they are known as osteosarcopenia. People with osteosarcopenia have an increased risk of falls, fractures and hospitalisations, and also a greatly reduced quality of life. In this interview we discus tools for assessing risk and appropriate management of the condition.   27 minute listen

General Specialty: Between the ages of 40 and 80 years, our total muscle mass is estimated to decline by 25% to 30%. Skeletal muscle plays a critically important role as a regulator of energy and protein metabolism throughout the body. As a result, age-related loss of muscle mass and strength can dramatically increase morbidity and mortality of otherwise survivable illness in older people. In this interview we talk about maintaining muscle mass in older adults. 31 minute listen

Epilepsy: For about 30% of patients with epilepsy, seizure control is not achieved despite optimal use of anticonvulsant medications. For these patients, surgery may be a viable treatment option and may help them manage their seizures and epilepsy much better, or possibly even cure it. Now there are many causes of epilepsy and so the strategies around treating that surgically differ widely, which is what we discuss in this interview…..
28-minute listen

Psychiatry: Respiratory: The onset of schizophrenia commonly occurs during adolescence and young adulthood. Tolerability and safety concerns are of particular importance in treatment selection because adolescents may be more vulnerable to adverse effects associated with medications. In this interview we talk with Prof. Thompson from EPPIC, EPPIC works with young people with psychotic disorders and aims to facilitate the early identification and treatment of psychosis and therefore reduce the disruption to the young person’s functioning and psychosocial development.

Psychiatry: Sexual difficulties are common. They’re even more common in people who are depressed. And they’re even more common again in depressed people who are taking antidepressant therapies. It’s important to include sexual functioning as a routine part of practice, however, talking about sex and sexual dysfunction is still often an uncomfortable topic of discussion for both patients and their psychiatrist. In this interview we discuss the when, where and how?

Respiratory: ‘Real world evidence’ is a bit of a buzz word in research circles at the moment. Increasingly this type of evidence is being used to inform both regulatory and payor decision-making. But what does it mean clinically? And should we be paying attention? In this interview we discuss real world evidence, with a particular focus on severe asthma biologics.
23-minute listen

The Australian Mepolizumab Registry is an investigator-initiated and managed study funded through the GlaxoSmithKline Investigator-Sponsored Studies program